• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Tuesday, August 9, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Price disclosure legislation unlikely to lower drug costs

Bioengineer by Bioengineer
January 22, 2019
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

CLEMSON, South Carolina — The Trump administration’s proposal to require pharmaceutical companies to publish drug prices in TV ads is unlikely to help control drug prices, according to a study publishing Jan. 22, 2019, in JAMA Internal Medicine.

The research found that consumer demand for high-priced drugs declined unless the drug ads included language explaining that the medication would be low-cost or no-cost because of insurance coverage or other discounts.

“In a world where coupon programs exist, consumers are unlikely to be influenced by price disclosures,” said Jace Garrett, an assistant professor of accounting in Clemson University’s College of Business and lead author of the study.

Coupon programs are a common marketing practice aimed at building market share. While they decrease a consumer’s out-of-pocket expense, they do not decrease the overall cost of the drug. The costs are passed along to insurance companies and, ultimately, find their way back to consumers in other channels.

Therefore, Garrett said, price disclosures are “unlikely to create competition necessary to drive down prices. Drug companies will still make money and the status quo would remain the same.”

“Will price disclosure work at all? The answer is yes: price disclosure works, absent anything else,” said co-author Bill Tayler, professor of accounting at Brigham Young University. “But in a world where pharmaceutical companies behave logically, they will surely use a modifier of sorts that would unwind the entire benefit of this legislation.”

For the study, Garrett, Tayler and researchers at Johns Hopkins University showed 580 participants one of five ads for a fictional diabetes prescription drug, Mayzerium. (The study participants were not patients; they had been told to assume they had recently been diagnosed with type 2 diabetes.) The ad in the control condition made no mention of the drug’s price while the other four disclosed either a low ($50 a month) or a high ($15,500 a month) price. In two “modified” ads, language was included indicating that eligible patients may be able to get the drug for as little as $0 a month because of insurance coverage or coupon availability.

For the high-priced drug ad, price disclosure significantly reduced the likelihood of participants asking their doctor about the drug, asking their insurance provider about the drug or researching the drug online, or taking the drug. The participants who saw ads with modifying language were still interested in the drugs.

“Price disclosure in drug ads works only under the ‘tell the price, only the price, nothing but the price’ scenario,” said co-author Ge Bai, associate professor of accounting at the Johns Hopkins Carey Business School.

For the Trump proposal to be effective, the administration must do something about pharmaceutical companies’ use of copay assistance programs.

“If we really want to bring drug prices down, consumers have to vote with their wallets, and consumers are most likely to do that when they feel the pinch of high drug costs,” Garrett said.

Tayler agrees: “Legislation requiring pharmaceutical companies to provide equivalent discounts to all payers would do the trick. If the drug is marked down 90 percent for the patient, mark it down 90 percent for their insurer as well. That would keep pharmaceutical companies from gaming the system via handouts to consumers while forcing the insurers to carry the full cost of overpriced drugs.”

The Trump administration is not the first to try to combat skyrocketing pharmaceutical prices; previous administrations have done their best to address the issue, as have others in the medical and health care industries. Exactly how Trump’s Health and Human Services proposal will look is still unclear, and Big Pharma is already pushing back — and showing signs of doing exactly what researchers in this JAMA Internal Medicine article predict.

A recent op-ed in USA Today by the president of the Pharmaceutical Research and Manufacturers of America said the proposal would be confusing to patients and might deter them from seeking needed care. “List prices are not a good indicator of what patients will pay, because their insurers determine what they pay out of pocket,” wrote Stephen J. Ubl.

“The suggested policy is unlikely to do harm, but it is also unlikely to help much to control pharmaceutical prices,” Tayler said. “This is not the most effective route and it could be very costly in terms of the lawsuits that are going to result. Why fight the legal battle if it’s not going to work?”

The research was intended to help inform policymakers, but there’s also a message for consumers, Garrett said.

“For all we say about wanting transparency about prices, if our own decisions are always motivated by our financial self-interest, having price information might not make a difference,” Garret said.

“I’m getting the drug for zero, but who’s paying the full cost?”

###

Todd Hollingshead with BYU News contributed to this story.

Media Contact
Clinton Colemares
[email protected]
919-548-6493
http://newsstand.clemson.edu/?p=165732

Tags: Health CareInsuranceMedicine/HealthPharmaceutical Science
Share12Tweet7Share2ShareShareShare1

Related Posts

DrugVirus.info portal

New drug screening tool to fight the next pandemic

August 9, 2022
Likelihood of getting an updated COVID-19 booster among adults 50+

Most older adults ready to roll up sleeves this fall for updated COVID-19 boosters

August 9, 2022

Vancouver researchers suggest air pollution be included as risk factor for patients with lung cancer and have never smoked

August 9, 2022

Scientists have created optical fibers with unusual properties

August 8, 2022
Please login to join discussion

POPULAR NEWS

  • Picture of the horse specimen.

    Ancient DNA clarifies the early history of American colonial horses

    56 shares
    Share 22 Tweet 14
  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

    66 shares
    Share 26 Tweet 17
  • Ill-fated ‘Into the Wild’ adventurer was victim of unfortunate timing, Oregon State study suggests

    39 shares
    Share 16 Tweet 10
  • Skin: An additional tool for the versatile elephant trunk

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

UrbanizationVirusWeather/StormsUniversity of WashingtonZoology/Veterinary ScienceUrogenital SystemViolence/CriminalsVirologyWeaponryVaccineVaccinesVehicles

Recent Posts

  • Study finds genetic method for identifying hundreds of disease agents ‘promising’
  • UNH awarded $2.8 million to develop robots to care for people with Alzheimer’s and dementia
  • Southwest Research Institute develops, deploys automated shuttle for campus tours, research
  • Gene editing via CRISPR/Cas9 can lead to cell toxicity and genome instability
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In